Moderna embraces the "AI+ healthcare" trend! Collaborates with OpenAI to accelerate drug development

According to the Zhītōng Finance and Economics APP, Moderna (MRNA.US), a global leader in the biotechnology field known for its mRNA-based COVID-19 vaccine, announced on Wednesday local time that the company has partnered with OpenAI, the developer of ChatGPT, to deploy ChatGPT Enterprise across its entire business line to accelerate its drug development process.

Media reports indicate that as part of this significant collaboration, approximately 3,000 employees of the Massachusetts-based biotechnology company Moderna will have access to ChatGPT Enterprise based on OpenAI's cutting-edge large language model GPT-4 by the end of this week. However, the financial terms of this collaboration agreement have not been disclosed.

It is understood that the two companies began their collaboration in early 2023 and previously launched a customized version of ChatGPT called mChat. Since its launch, over 80% of Moderna's employees have been using this version for their daily drug development work.

In a joint statement, the two companies stated, "This initial collaboration has successfully accelerated the development of AI culture, fully driving the deployment of ChatGPT Enterprise and its enhanced key features, such as advanced micro-level analysis, image generation, and GPTs."

Stéphane Bancel, CEO of Moderna, stated, "Moderna has an ambitious plan to launch multiple significant products in the coming years, and collaboration with technology companies like OpenAI is crucial for our scalability and maximizing our impact on patients."

Sam Altman, CEO of OpenAI, said, "People are indeed talking about how artificial intelligence may one day cure diseases, and I think this is a very meaningful first step."

Previously, Recursion Pharmaceuticals (RXRX.US) had already entered into a comprehensive collaboration with AI chip leader NVIDIA (NVDA.US) in 2023 to jointly develop drug development processes based on artificial intelligence technology.

Certified as the "Father of AI" - the "Golden Track"! "AI + Medical" is NVIDIA's Most Focused Subfield

As the helmsman of NVIDIA and known as the "Father of AI," Jensen Huang has repeatedly referred to "AI + medical technology/biology" as the next amazing revolution in the technology field in various public occasions. He even boldly stated at a recent conference that the era when everyone must learn computers is over, and biology and medicine are the future for humanity. Over the past two years, NVIDIA's venture capital department has invested a significant portion of funds in the drug development field - in 2023 alone, NVIDIA invested in 8 early-stage biotech companies focusing on drug development The application of AI technology in the field of healthcare has made significant progress, especially in areas such as new drug discovery, simulated gene editing, disease diagnosis, patient monitoring, and medical image analysis. For example, NVIDIA provides strong computational hardware support and AI software tools support to the healthcare field through its high computing power-supported BioNeMo cloud service and other AI platforms, accelerating the process of drug research and disease diagnosis and treatment. Behind technologies such as drug discovery integrated with AI large models and medical imaging, NVIDIA GPUs and NVIDIA software ecosystem may play a crucial role in providing powerful computational support.

Undoubtedly, with the continuous advancement of AI technology, more innovative medical applications are expected to emerge in the future, such as drug testing using AI-simulated virtual patients and precise gene editing simulation processes using AI.

According to the latest research report from GMI Research, the market value of the healthcare sector integrating AI technology is only about $10.4 billion in 2022, and is expected to reach $189.9 billion by 2030, with a high compound annual growth rate (CAGR) of 43.7% during this period. GMI Research expects AI to be widely applied in medical imaging, drug discovery, medical surgical assistance robots, gene-level precision medicine, and other fields, significantly reducing product innovation cycles, greatly improving the precision of modern medicine, and covering a larger range of patients in the same amount of time